What do systematic reviews say?

Progesterone vs hCG regimens

Progesterone may leads to lower OHSS compared with hCG regimens (low certainty).

• Luteal phase support for assisted reproduction cycles 2015 · Cochrane Headline outcomes only
  OR 0.46 [0.3, 0.71]
  5 studies · 1293 participants
  Low

300 mg vaginal progesterone vs vaginal progesterone

It is very uncertain whether 300 mg vaginal progesterone changes ongoing pregnancy rate compared with 600 mg vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 1.58 [0.81, 3.09]
  1 study · 200 participants
  Very low

300 mg vaginal progesterone vs vaginal progesterone

It is very uncertain whether 300 mg vaginal progesterone changes multiple pregnancy rate compared with 600 mg vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 0.5 [0.05, 5.43]
  1 study · 200 participants
  Very low

Intramuscular (IM) progesterone vs vaginal progesterone

The review found no eligible studies for this question.

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intramuscular (IM) progesterone vs vaginal progesterone

It is very uncertain whether intramuscular (IM) progesterone changes ongoing pregnancy rate compared with vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 0.59 [0.34, 1.02]
  1 study · 225 participants
  Very low

Intramuscular (IM) progesterone vs vaginal progesterone

It is very uncertain whether intramuscular (IM) progesterone changes miscarriage rate compared with vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 0.75 [0.43, 1.32]
  1 study · 81 participants
  Very low

Intramuscular (IM) progesterone vs vaginal progesterone

It is very uncertain whether intramuscular (IM) progesterone changes clinical pregnancy rate compared with vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 0.78 [0.55, 1.11]
  1 study · 225 participants
  Very low

Intramuscular (IM) progesterone vs vaginal progesterone

The review found no eligible studies for this question.

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intramuscular (IM) progesterone vs vaginal progesterone

It is very uncertain whether intramuscular (IM) progesterone changes adverse events  compared with vaginal progesterone (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 9.25 [2.21, 38.78]
  1 study · 225 participants
  Very low

Intramuscular (IM) progesterone vs vaginal progesterone

The review found no eligible studies for this question.

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aqueous subcutaneous (Sc) progesterone vs vaginal progesterone

It is very uncertain whether aqueous subcutaneous (Sc) progesterone changes ongoing pregnancy rate compared with vaginal progesterone gel (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 1.05 [0.54, 2.05]
  1 study · 246 participants
  Very low

Aqueous subcutaneous (Sc) progesterone vs vaginal progesterone

It is very uncertain whether aqueous subcutaneous (Sc) progesterone changes clinical pregnancy rate compared with vaginal progesterone gel (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 1.12 [0.59, 2.11]
  1 study · 246 participants
  Very low

Vaginal progesterone vs GnRH agonist

It is very uncertain whether vaginal progesterone changes clinical pregnancy rate compared with gonadotropin‐releasing hormone (GnRH) agonist (very low certainty).

• Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse 2022 · Cochrane Headline outcomes only
  RR 1 [0.51, 1.95]
  1 study · 242 participants
  Very low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 32 participants
  Low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

GnRH‐a + medroxyprogesterone acetate may leads to lower rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  RR 0.13 [0.02, 0.84]
  1 study · 16 participants
  Low

Summary of findings table ‐ Progestogens vs GnRH antagonists

• Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 120 participants
  GRADE not reported